Norris Perne & French LLP Charles River Laboratories International, Inc. Transaction History

Norris Perne & French LLP

  • $1.3 Billion
  • Q2 2024

A detailed history of Norris Perne & French LLP transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Norris Perne & French LLP holds 130,537 shares of CRL stock, worth $29 Million. This represents 2.08% of its overall portfolio holdings.

Number of Shares
130,537
Previous 128,630 1.48%
Holding current value
$29 Million
Previous $34.9 Million 22.63%
% of portfolio
2.08%
Previous 2.67%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 24, 2024
BUY
$206.39 - $268.73 $393,585 - $512,468
1,907 Added 1.48%
130,537 $27 Million
Q1 2024

Apr 16, 2024
SELL
$203.52 - $273.43 $684,437 - $919,545
-3,363 Reduced 2.55%
128,630 $34.9 Million
Q4 2023

Jan 22, 2024
BUY
$164.52 - $238.84 $4.62 Million - $6.71 Million
28,103 Added 27.05%
131,993 $31.2 Million
Q3 2023

Oct 18, 2023
BUY
$194.44 - $217.61 $209,411 - $234,365
1,077 Added 1.05%
103,890 $20.4 Million
Q2 2023

Jul 19, 2023
BUY
$183.71 - $210.25 $232,760 - $266,386
1,267 Added 1.25%
102,813 $21.6 Million
Q1 2023

Apr 20, 2023
BUY
$191.89 - $259.92 $177,882 - $240,945
927 Added 0.92%
101,546 $20.5 Million
Q4 2022

Jan 24, 2023
SELL
$197.11 - $250.07 $450,199 - $571,159
-2,284 Reduced 2.22%
100,619 $0
Q3 2022

Oct 13, 2022
BUY
$182.44 - $250.54 $441,504 - $606,306
2,420 Added 2.41%
102,903 $20.3 Million
Q2 2022

Aug 11, 2022
BUY
$204.13 - $302.4 $5.17 Million - $7.66 Million
25,343 Added 33.73%
100,483 $21.5 Million
Q1 2022

Apr 26, 2022
BUY
$255.51 - $362.11 $434,622 - $615,949
1,701 Added 2.32%
75,140 $21.3 Million
Q4 2021

Jan 26, 2022
SELL
$351.38 - $448.68 $490,877 - $626,805
-1,397 Reduced 1.87%
73,439 $27.7 Million
Q3 2021

Oct 26, 2021
BUY
$372.64 - $458.3 $117,381 - $144,364
315 Added 0.42%
74,836 $30.9 Million
Q2 2021

Jul 20, 2021
SELL
$294.17 - $371.65 $2.39 Million - $3.02 Million
-8,132 Reduced 9.84%
74,521 $27.6 Million
Q1 2021

Apr 30, 2021
SELL
$249.67 - $299.48 $6.23 Million - $7.47 Million
-24,934 Reduced 23.18%
82,653 $24 Million
Q4 2020

Jan 27, 2021
SELL
$222.0 - $252.62 $168,276 - $191,485
-758 Reduced 0.7%
107,587 $26.9 Million
Q3 2020

Oct 26, 2020
SELL
$175.56 - $226.45 $221,732 - $286,006
-1,263 Reduced 1.15%
108,345 $24.5 Million
Q2 2020

Jul 23, 2020
SELL
$118.84 - $189.72 $196,799 - $314,176
-1,656 Reduced 1.49%
109,608 $19.1 Million
Q1 2020

Apr 16, 2020
BUY
$98.9 - $178.34 $1.21 Million - $2.18 Million
12,222 Added 12.34%
111,264 $14 Million
Q4 2019

Jan 22, 2020
BUY
$126.05 - $152.76 $109,663 - $132,901
870 Added 0.89%
99,042 $15.1 Million
Q3 2019

Oct 24, 2019
SELL
$125.07 - $143.67 $244,887 - $281,305
-1,958 Reduced 1.96%
98,172 $13 Million
Q2 2019

Jul 19, 2019
BUY
$123.4 - $148.55 $936,112 - $1.13 Million
7,586 Added 8.2%
100,130 $14.2 Million
Q1 2019

Apr 29, 2019
SELL
$104.82 - $146.73 $255,236 - $357,287
-2,435 Reduced 2.56%
92,544 $13.4 Million
Q4 2018

Jan 28, 2019
SELL
$105.09 - $137.23 $102,252 - $133,524
-973 Reduced 1.01%
94,979 $10.8 Million
Q3 2018

Oct 29, 2018
SELL
$112.11 - $134.54 $129,150 - $154,990
-1,152 Reduced 1.19%
95,952 $12.9 Million
Q2 2018

Jul 24, 2018
SELL
$102.37 - $117.25 $249,680 - $285,972
-2,439 Reduced 2.45%
97,104 $10.9 Million
Q1 2018

Apr 17, 2018
SELL
$98.19 - $115.2 $73,838 - $86,630
-752 Reduced 0.75%
99,543 $10.6 Million
Q4 2017

Jan 23, 2018
BUY
$100.43 - $118.09 $141,907 - $166,861
1,413 Added 1.43%
100,295 $11 Million
Q3 2017

Nov 01, 2017
BUY
$96.72 - $109.26 $9.56 Million - $10.8 Million
98,882
98,882 $10.7 Million

Others Institutions Holding CRL

# of Institutions
728
Shares Held
50.9M
Call Options Held
183K
Put Options Held
346K
View Full List

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CRL Quotes by TradingView
  • Ticker CRL
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 50,863,300
  • Market Cap $11.3B
  • Description
  • Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...
More about CRL
Track This Portfolio

Track Norris Perne & French LLP Portfolio

Follow Norris Perne & French LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norris Perne & French LLP, based on Form 13F filings with the SEC.

News

Stay updated on Norris Perne & French LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email